PD-1/PD-L1, JAK Drugs to Be Exempt from Spillover Price Cuts: Chuikyo

Chuikyo Drug Pricing Subcommittee Meeting on March 13 Japan’s health ministry on March 13 said it intends to exclude PD-1/PD-L1 and JAK inhibitors from the list of drugs subject to the so-called “spillover” from the market expansion re-pricing of other...read more